Amgen (NASDAQ: AMGN) has recently received a number of price target changes and ratings updates:
- 8/20/2026 – Amgen had its price target raised by Piper Sandler from $427.00 to $457.00. They now have an “overweight” rating on the stock.
- 8/19/2026 – Amgen had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $362.00 price target on the stock.
- 8/19/2026 – Amgen had its price target raised by Argus from $375.00 to $460.00. They now have a “buy” rating on the stock.
- 8/18/2026 – Amgen had its price target raised by Cantor Fitzgerald from $350.00 to $400.00. They now have a “neutral” rating on the stock.
- 8/18/2026 – Amgen had its price target raised by Mizuho from $303.00 to $352.00. They now have a “neutral” rating on the stock.
- 8/14/2026 – Amgen had its price target raised by Barclays PLC from $360.00 to $380.00. They now have an “equal weight” rating on the stock.
- 8/10/2026 – Amgen had its price target raised by Guggenheim from $343.00 to $388.00. They now have a “neutral” rating on the stock.
- 8/8/2026 – Amgen was upgraded by Wall Street Zen from “hold” to “buy”.
- 8/7/2026 – Amgen had its price target raised by Citigroup Inc. from $345.00 to $405.00. They now have a “neutral” rating on the stock.
- 8/6/2026 – Amgen was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
- 8/6/2026 – Amgen had its price target raised by Sanford C. Bernstein from $335.00 to $345.00. They now have a “market perform” rating on the stock.
- 8/5/2026 – Amgen had its price target raised by Scotiabank from $385.00 to $450.00. They now have an “outperform” rating on the stock.
- 8/5/2026 – Amgen had its price target raised by UBS Group AG from $420.00 to $440.00. They now have a “buy” rating on the stock.
- 8/5/2026 – Amgen had its price target raised by TD Cowen from $420.00 to $452.00. They now have a “buy” rating on the stock.
- 8/5/2026 – Amgen had its price target raised by Scotiabank from $385.00 to $450.00. They now have a “sector outperform” rating on the stock.
- 8/5/2026 – Amgen had its price target raised by Truist Financial Corporation from $340.00 to $362.00. They now have a “hold” rating on the stock.
- 8/5/2026 – Amgen had its price target raised by Oppenheimer Holdings, Inc. from $400.00 to $450.00. They now have an “outperform” rating on the stock.
- 8/5/2026 – Amgen had its price target raised by Morgan Stanley from $333.00 to $351.00. They now have an “equal weight” rating on the stock.
- 8/5/2026 – Amgen had its price target raised by Royal Bank Of Canada from $370.00 to $400.00. They now have an “outperform” rating on the stock.
- 8/5/2026 – Amgen had its price target raised by Robert W. Baird from $215.00 to $230.00. They now have an “underperform” rating on the stock.
- 8/5/2026 – Amgen had its price target raised by Bank of America Corporation from $312.00 to $317.00. They now have an “underperform” rating on the stock.
- 8/5/2026 – Amgen had its price target raised by Canaccord Genuity Group Inc. from $366.00 to $384.00. They now have a “hold” rating on the stock.
- 8/5/2026 – Amgen had its price target raised by Wells Fargo & Company from $390.00 to $400.00. They now have an “equal weight” rating on the stock.
- 8/5/2026 – Amgen had its price target raised by BMO Capital Markets from $400.00 to $450.00. They now have an “outperform” rating on the stock.
- 7/29/2026 – Amgen had its price target raised by Barclays PLC from $350.00 to $360.00. They now have an “equal weight” rating on the stock.
- 7/15/2026 – Amgen was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.
- 7/13/2026 – Amgen had its price target raised by UBS Group AG from $400.00 to $420.00. They now have a “buy” rating on the stock.
- 7/13/2026 – Amgen had its price target raised by Guggenheim from $340.00 to $343.00. They now have a “neutral” rating on the stock.
- 7/8/2026 – Amgen had its price target lowered by Morgan Stanley from $340.00 to $333.00. They now have an “equal weight” rating on the stock.
- 7/7/2026 – Amgen had its price target raised by Truist Financial Corporation from $327.00 to $340.00. They now have a “hold” rating on the stock.
- 7/6/2026 – Amgen had its “neutral” rating reaffirmed by Cantor Fitzgerald. They now have a $350.00 price target on the stock.
Amgen Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.3%. The ex-dividend date is Friday, August 21st. Amgen’s dividend payout ratio (DPR) is 62.65%.
Insider Activity at Amgen
In related news, SVP Rachna Khosla sold 1,252 shares of the firm’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the transaction, the senior vice president directly owned 6,404 shares of the company’s stock, valued at approximately $2,666,817.72. This trade represents a 16.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Nancy A. Grygiel sold 2,970 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 6,222 shares of company stock worth $2,540,926 over the last 90 days. Corporate insiders own 0.85% of the company’s stock.
Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.
Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.
Featured Stories
- Five stocks we like better than Amgen
- Palantir’s Sovereign AI Pitch Tests Microsoft’s Cloud-First AI Bet
- Salesforce Looks Overbought, But the Rally May Be Far From Over
- Radar Anomaly: Draganfly’s Options Surge Signals Strategy Shift
- Boarding Call: EHang Secures First-Mover Altitude
Receive News & Ratings for Amgen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc and related companies with MarketBeat.com's FREE daily email newsletter.
